SWG 5: The primary purpose of the Curative Therapies SWG is to accelerate work toward a cure for HIV, by linking local investigators of curative therapies for HIV to the UW/FHCRC CFAR. SWG 5 will leverage a large NIH investment in the Seattle-led consortium defeat HIV, one of three Martin Delaney collaboratories focused on the cure of HIV. We intend to facilitate use of CFAR resources, including the clinical, basic science, and developmental cores, to leverage efficiencies of scale, develop novel research questions, and collectively pursue additional NIH and foundation-sponsored resources for the study of curative therapies for HIV. A secondary purpose is to link Seattle investigators with outside leaders in the field, to develop local expertise as well as enhance areas of local strength. These activities will add value to the UW/FHCRC CFAR, US CFARs generally, and defeat HIV, by establishing an international center of excellence in the study of curative therapies for HIV. SWG 6: The Substance Abuse (SA) SWG will consist of over 30 UW investigators working in four research emphasis areas: Sexual Behavior-Substance Abuse Nexus, Substance Abusing HIV Positive Individuals, Prevention of HIV among Substance Abusing Individuals, HIV/STI Epidemiology among Substance Abusers.
The aims of the SWG 6 are: 1) develop synergy and collaboration among local HIV substance abuse researchers, and 2) seek funding for identified collaborative opportunities and encourage early career and minority investigators to pursue substance abuse and HIV/STI related research. The success of the SA SWG will be determined by publication of manuscripts or acceptance of abstracts, and/or submissions for grant funding by SA SWG members and other CFAR investigators. SWG 7: Coverage gaps with efficacious interventions underscore the importance of improving knowledge translation and implementation to achieve scale.
The aim of the Implementation Science SWG is to improve the speed, efficiency and quality of translation of scientific evidence on HIV/STI prevention and care into effective, large scale health programs. SWG 7 will leverage local and international multidisciplinary expertise to develop innovative models for implementing and scaling-up efficacious HIV/STI interventions, and apply rigorous methods to develop a base of evidence to guide scale-up. Specific activities include bimonthly IS meetings to develop novel research methods for IS, foster interdisciplinary collaboration, and coordinate responses to funding opportunities; annual IS symposia; fostering collaboration among CFAR cores and extra-CFAR institutions; and IS education, training and mentoring internationally and at the UW.

Public Health Relevance

Our 3 proposed SWGs propose to promote collaborations and accelerate the pace of research in three areas: Curative Therapies for HIV, bringing together scientists with many different areas of expertise to help them work toward a cure for HIV; Substance Abuse and HIV/STI, addressing the challenges presented by the intersection of substance abuse and HIV infection; and Implementation Science, providing critical resources to improve the quality of research and maximize the impact of HIV interventions worldwide.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027757-30
Application #
9285720
Study Section
Special Emphasis Panel (ZAI1-UKS-A)
Project Start
Project End
Budget Start
2017-06-01
Budget End
2018-05-31
Support Year
30
Fiscal Year
2017
Total Cost
$5
Indirect Cost
$2
Name
University of Washington
Department
Type
Domestic Higher Education
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Fredericksen, Rob J; Mayer, Kenneth H; Gibbons, Laura E et al. (2018) Development and Content Validation of a Patient-Reported Sexual Risk Measure for Use in Primary Care. J Gen Intern Med 33:1661-1668
Wilson, Kate S; Wanje, George; Masese, Linnet et al. (2018) A Prospective Cohort Study of Fertility Desire, Unprotected Sex, and Detectable Viral Load in HIV-Positive Female Sex Workers in Mombasa, Kenya. J Acquir Immune Defic Syndr 78:276-282
Ikoma, Minako; Gantt, Soren; Casper, Corey et al. (2018) KSHV oral shedding and plasma viremia result in significant changes in the extracellular tumorigenic miRNA expression profile in individuals infected with the malaria parasite. PLoS One 13:e0192659
Grover, Surbhi; Desir, Fidel; Jing, Yuezhou et al. (2018) Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis. J Acquir Immune Defic Syndr 79:421-429
Gómez, Laurén A; Crowell, Claudia S; Njuguna, Irene et al. (2018) Improved Neurodevelopment After Initiation of Antiretroviral Therapy in Human Immunodeficiency Virus-infected Children. Pediatr Infect Dis J 37:916-922
Thomson, Kerry A; Dhanireddy, Shireesha; Andrasik, Michele et al. (2018) Fertility desires and preferences for safer conception strategies among people receiving care for HIV at a publicly-funded clinic in Seattle, WA. AIDS Care 30:121-129
Lohman-Payne, Barbara; Gabriel, Benjamin; Park, Sangshin et al. (2018) HIV-exposed uninfected infants: elevated cord blood Interleukin 8 (IL-8) is significantly associated with maternal HIV infection and systemic IL-8 in a Kenyan cohort. Clin Transl Med 7:26
McGrath, Christine J; Singa, Benson; Langat, Agnes et al. (2018) Non-disclosure to male partners and incomplete PMTCT regimens associated with higher risk of mother-to-child HIV transmission: a national survey in Kenya. AIDS Care 30:765-773
Njuguna, Irene N; Wagner, Anjuli D; Omondi, Vincent O et al. (2018) Financial Incentives for Pediatric HIV Testing in Kenya. Pediatr Infect Dis J 37:1142-1144

Showing the most recent 10 out of 1275 publications